Indian Pharma Market sees 12.1 percent growth in August: AIOCD-AWACS Report
New Delhi: The Indian Pharmaceutical Market (IPM) saw significant growth of 12.1 percent in value and 4.8 percent in volume, in the month of August, 2022, says market research firm All India Organization of Chemists and Druggists (AIOCD-AWACS).
"A robust 12% growth of the IPM seems to be supported by a good volume driven growth for majority of the therapy areas," the AWACS report said. It also claimed that COVID influence had reduced drastically by July 21 last year and most of the therapies had started following the normal seasonal trends. For the month of August 22, price increase led growth seems to be slightly higher than the volume growth.
IPM recorded sales of Rs 16,239 crore for August month, and most of the therapies showed a well balanced double digit value and unit growth.
The fastest growing categories were cardiac which grew at 13 percent, anti-infectives - 13 percent and gastrointestinal - 12 percent. Anti-diabetes and vitamins grew 9 percent respectively. The month of August saw very few launches in the the Sitagliptin Generics segment.
Medical Dialogues team had earlier reported that IPM had witnessed a significant growth of 14.1% in value and 7.3% in volume in the month of July across all the therapy areas.
Also Read: Indian Pharma Market Sees 14.1 Percent Growth In July Sales: AIOCD-AWACS Report
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.